Benoxaprofen

Identification

Name
Benoxaprofen
Accession Number
DB04812
Type
Small Molecule
Groups
Withdrawn
Description

The use of benoxaprofen, formerly marketed as Oraflex tablets, was associated with fatal cholestatic jaundice among other serious adverse reactions. The holder of the approved application voluntarily withdrew Oraflex tablets from the market on August 5, 1982.

Structure
Thumb
Synonyms
  • (1)-2-(4-Chlorophenyl)benzoxazole-5-propionic acid
  • 2-(2-(4-Chlorophenyl)-1,3-benzoxazol-5-yl)propanoic acid
  • 2-(4-Chlorophenyl)-alpha-methyl-5-benzoxazoleacetic acid
  • 2-[2-(4-Chlorophenyl)-1,3-benzoxazol-5-yl]propanoic acid
  • Benoxaprofene
  • Benoxaprofeno
  • Benoxaprofenum
  • DL-benoxaprofen
International/Other Brands
Coxigon (Lilly) / Inflamid (Lilly) / Opren (Lilly) / Oraflex (Lilly)
Categories
UNII
17SZX404IM
CAS number
51234-28-7
Weight
Average: 301.724
Monoisotopic: 301.050570962
Chemical Formula
C16H12ClNO3
InChI Key
MITFXPHMIHQXPI-UHFFFAOYSA-N
InChI
InChI=1S/C16H12ClNO3/c1-9(16(19)20)11-4-7-14-13(8-11)18-15(21-14)10-2-5-12(17)6-3-10/h2-9H,1H3,(H,19,20)
IUPAC Name
2-[2-(4-chlorophenyl)-1,3-benzoxazol-5-yl]propanoic acid
SMILES
CC(C(O)=O)C1=CC2=C(OC(=N2)C2=CC=C(Cl)C=C2)C=C1

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limoneneThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with (4R)-limonene.Investigational
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with 19-norandrostenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with 5-androstenedione.Experimental, Illicit
AbciximabBenoxaprofen may increase the anticoagulant activities of Abciximab.Approved
AcebutololBenoxaprofen may decrease the antihypertensive activities of Acebutolol.Approved, Investigational
AceclofenacThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Aceclofenac.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Acemetacin.Approved, Experimental, Investigational
AcenocoumarolBenoxaprofen may increase the anticoagulant activities of Acenocoumarol.Approved, Investigational
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Acetylsalicylic acid.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Benoxaprofen.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Alclofenac.Approved, Withdrawn
AlclometasoneThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Aldosterone.Experimental, Investigational
Alendronic acidThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Alendronic acid.Approved
AliskirenBenoxaprofen may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlminoprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Alminoprofen.Experimental
AlprenololBenoxaprofen may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Benoxaprofen.Approved, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Amcinonide.Approved
AmikacinThe risk or severity of nephrotoxicity can be increased when Benoxaprofen is combined with Amikacin.Approved, Investigational, Vet Approved
AmilorideBenoxaprofen may decrease the antihypertensive activities of Amiloride.Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Aminosalicylic Acid.Approved
AmlodipineThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Benoxaprofen.Approved
AncrodBenoxaprofen may increase the anticoagulant activities of Ancrod.Approved, Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Andrographolide.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Androstenedione.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Anecortave.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with anecortave acetate.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Anisodamine.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Antipyrine.Approved, Investigational
Antithrombin III humanBenoxaprofen may increase the anticoagulant activities of Antithrombin III human.Approved
AntrafenineThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Antrafenine.Approved
ApixabanBenoxaprofen may increase the anticoagulant activities of Apixaban.Approved
ApocyninThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Apocynin.Investigational
ApramycinBenoxaprofen may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Apremilast.Approved, Investigational
ArbekacinBenoxaprofen may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved, Investigational
ArdeparinBenoxaprofen may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanBenoxaprofen may increase the anticoagulant activities of Argatroban.Approved, Investigational
ArotinololBenoxaprofen may decrease the antihypertensive activities of Arotinolol.Investigational
AsenapineBenoxaprofen may decrease the antihypertensive activities of Asenapine.Approved
AtamestaneThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Atamestane.Investigational
AtenololBenoxaprofen may decrease the antihypertensive activities of Atenolol.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Azapropazone.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Benoxaprofen.Approved
Azficel-TThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Azficel-T.Approved, Investigational
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Benoxaprofen.Approved, Investigational
AzosemideThe therapeutic efficacy of Azosemide can be decreased when used in combination with Benoxaprofen.Investigational
BacitracinThe risk or severity of nephrotoxicity can be increased when Benoxaprofen is combined with Bacitracin.Approved, Vet Approved
BalsalazideThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Balsalazide.Approved, Investigational
BecaplerminBenoxaprofen may increase the anticoagulant activities of Becaplermin.Approved, Investigational
Beclomethasone dipropionateThe risk or severity of gastrointestinal irritation can be increased when Beclomethasone dipropionate is combined with Benoxaprofen.Approved, Investigational
BefunololBenoxaprofen may decrease the antihypertensive activities of Befunolol.Experimental
BekanamycinBenoxaprofen may decrease the excretion rate of Bekanamycin which could result in a higher serum level.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Benazepril.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Bendazac.Experimental
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Benoxaprofen.Approved
BenorilateThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Benorilate.Experimental
BenzthiazideThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Benoxaprofen.Approved
BenzydamineThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Benzydamine.Approved
BepridilThe therapeutic efficacy of Bepridil can be decreased when used in combination with Benoxaprofen.Approved, Withdrawn
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Benoxaprofen.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Betamethasone.Approved, Vet Approved
BetaxololBenoxaprofen may decrease the antihypertensive activities of Betaxolol.Approved, Investigational
BetrixabanThe risk or severity of bleeding can be increased when Betrixaban is combined with Benoxaprofen.Approved, Investigational
BevantololBenoxaprofen may decrease the antihypertensive activities of Bevantolol.Approved
BevoniumThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Bevonium.Experimental
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Benoxaprofen.Approved, Investigational
BisoprololBenoxaprofen may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinBenoxaprofen may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BopindololBenoxaprofen may decrease the antihypertensive activities of Bopindolol.Approved
BromfenacThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Bromfenac.Approved
BucillamineThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Bucillamine.Investigational
BucindololBenoxaprofen may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of gastrointestinal irritation can be increased when Budesonide is combined with Benoxaprofen.Approved
BufexamacThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Bufexamac.Approved, Experimental
BufuralolBenoxaprofen may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumadizoneThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Bumadizone.Experimental
BumetanideThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Benoxaprofen.Approved
BupranololBenoxaprofen may decrease the antihypertensive activities of Bupranolol.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Benoxaprofen.Experimental
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Benoxaprofen.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Candoxatril.Experimental
CapsaicinThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Capsaicin.Approved
CaptoprilThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Captopril.Approved
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Carbaspirin calcium.Experimental, Investigational
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Benoxaprofen.Approved
CarprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Carprofen.Approved, Vet Approved, Withdrawn
CarteololBenoxaprofen may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolBenoxaprofen may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Benoxaprofen.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Celecoxib.Approved, Investigational
CeliprololBenoxaprofen may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CertoparinBenoxaprofen may increase the anticoagulant activities of Certoparin.Approved, Investigational
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Benoxaprofen.Approved, Investigational, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Benoxaprofen.Approved, Vet Approved
ChlorphenesinThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Chlorphenesin.Approved, Vet Approved, Withdrawn
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Benoxaprofen.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Benoxaprofen resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Choline magnesium trisalicylate.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Cilazapril.Approved
CimicoxibThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Cimicoxib.Investigational
CinoxacinBenoxaprofen may increase the neuroexcitatory activities of Cinoxacin.Approved, Investigational, Withdrawn
CiprofloxacinBenoxaprofen may increase the neuroexcitatory activities of Ciprofloxacin.Approved, Investigational
CisplatinThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Cisplatin.Approved
ClobetasolThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Clobetasol.Approved, Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Clobetasol propionate.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Clobetasone.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Clocortolone.Approved
Clodronic AcidThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Clodronic Acid.Approved, Investigational, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Clonixin.Approved
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Benoxaprofen.Vet Approved
CloranololBenoxaprofen may decrease the antihypertensive activities of Cloranolol.Experimental
ColesevelamColesevelam can cause a decrease in the absorption of Benoxaprofen resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Benoxaprofen resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Cortexolone 17α-propionate.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Corticosterone.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Cortisone acetate.Approved, Investigational
CurcuminThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Curcumin.Approved, Investigational
CyclopenthiazideThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Benoxaprofen.Experimental
CyclosporineThe risk or severity of renal failure and hypertension can be increased when Benoxaprofen is combined with Cyclosporine.Approved, Investigational, Vet Approved
Dabigatran etexilateBenoxaprofen may increase the anticoagulant activities of Dabigatran etexilate.Approved
DalteparinBenoxaprofen may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidBenoxaprofen may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DarexabanBenoxaprofen may increase the anticoagulant activities of Darexaban.Investigational
DeferasiroxThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Deferasirox.Approved, Investigational
DeflazacortThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Deflazacort.Approved, Investigational
DelaprilThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Delapril.Investigational
DesipramineBenoxaprofen may decrease the antihypertensive activities of Desipramine.Approved, Investigational
DesirudinBenoxaprofen may increase the anticoagulant activities of Desirudin.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Desmopressin.Approved
DesonideThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Desonide.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DexamethasoneThe risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Benoxaprofen.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Dexamethasone isonicotinate.Vet Approved
DexibuprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Dexibuprofen.Approved, Investigational
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Benoxaprofen.Approved, Investigational
DexniguldipineThe therapeutic efficacy of Dexniguldipine can be decreased when used in combination with Benoxaprofen.Experimental
DextranBenoxaprofen may increase the anticoagulant activities of Dextran.Approved, Investigational, Vet Approved
DibekacinBenoxaprofen may decrease the excretion rate of Dibekacin which could result in a higher serum level.Experimental
Dibotermin alfaThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Dibotermin alfa.Approved, Investigational
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Benoxaprofen.Approved, Vet Approved
DicoumarolBenoxaprofen may increase the anticoagulant activities of Dicoumarol.Approved
DifenpiramideThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Difenpiramide.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Diflunisal.Approved, Investigational
DifluocortoloneThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Difluocortolone.Approved, Investigational, Withdrawn
DifluprednateThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Difluprednate.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Benoxaprofen.Approved
DihydrostreptomycinBenoxaprofen may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Investigational, Vet Approved
DiltiazemThe therapeutic efficacy of Diltiazem can be decreased when used in combination with Benoxaprofen.Approved, Investigational
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Benoxaprofen.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Benoxaprofen.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Benoxaprofen.Approved
DoxazosinThe therapeutic efficacy of Doxazosin can be decreased when used in combination with Benoxaprofen.Approved
DrospirenoneBenoxaprofen may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Droxicam.Withdrawn
DuvelisibThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Duvelisib.Investigational
E-6201The risk or severity of adverse effects can be increased when Benoxaprofen is combined with E-6201.Investigational
Edetic AcidBenoxaprofen may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanBenoxaprofen may increase the anticoagulant activities of Edoxaban.Approved
EfonidipineThe therapeutic efficacy of Efonidipine can be decreased when used in combination with Benoxaprofen.Approved, Investigational
EnalaprilThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Enalaprilat.Approved
EnoxacinBenoxaprofen may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational
EnoxaparinBenoxaprofen may increase the anticoagulant activities of Enoxaparin.Approved
EnprostilThe therapeutic efficacy of Enprostil can be decreased when used in combination with Benoxaprofen.Experimental
EpanololBenoxaprofen may decrease the antihypertensive activities of Epanolol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Epirizole.Approved
EpitizideThe therapeutic efficacy of Epitizide can be decreased when used in combination with Benoxaprofen.Experimental
EplerenoneBenoxaprofen may decrease the antihypertensive activities of Eplerenone.Approved
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Benoxaprofen.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Benoxaprofen.Approved
EquileninThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Equilin.Approved
EsatenololBenoxaprofen may decrease the antihypertensive activities of Esatenolol.Experimental
EsmololBenoxaprofen may decrease the antihypertensive activities of Esmolol.Approved
EstroneThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Estrone sulfate.Approved
Etacrynic acidThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Benoxaprofen.Approved, Investigational
EtanerceptThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Etanercept.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Ethenzamide.Experimental
Ethyl biscoumacetateBenoxaprofen may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Etofenamate.Approved, Investigational
EtoricoxibThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Etoricoxib.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Evening primrose oil.Investigational, Nutraceutical
ExisulindThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Exisulind.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Felbinac.Experimental
FelodipineThe therapeutic efficacy of Felodipine can be decreased when used in combination with Benoxaprofen.Approved, Investigational
FenbufenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Fenbufen.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Fenoprofen.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Benoxaprofen.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Fentiazac.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Feprazone.Experimental
Ferulic acidBenoxaprofen may increase the anticoagulant activities of Ferulic acid.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Benoxaprofen.Approved, Investigational
FleroxacinBenoxaprofen may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Benoxaprofen.Approved, Withdrawn
FluasteroneThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Fluasterone.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Fludrocortisone.Approved, Investigational
FluindioneBenoxaprofen may increase the anticoagulant activities of Fluindione.Approved, Investigational
FlumequineBenoxaprofen may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Flunisolide.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Flunixin.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Flunoxaprofen.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Fluorometholone.Approved, Investigational
FluprednideneThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Benoxaprofen.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Flurbiprofen.Approved, Investigational
FluticasoneThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Fluticasone.Approved, Experimental, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Fluticasone furoate.Approved
Fluticasone propionateThe risk or severity of gastrointestinal irritation can be increased when Fluticasone propionate is combined with Benoxaprofen.Approved
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Benoxaprofen.Approved, Nutraceutical, Vet Approved
FondaparinuxBenoxaprofen may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Benoxaprofen.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Formestane.Approved, Investigational, Withdrawn
FosinoprilThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Benoxaprofen is combined with Fosinopril.Approved
FramycetinBenoxaprofen may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemideThe therapeutic efficacy of Furosemide can be decreased when used in combination with Benoxaprofen.Approved, Vet Approved
GabexateBenoxaprofen may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinBenoxaprofen may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinBenoxaprofen may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Benoxaprofen.Approved, Withdrawn
GemifloxacinBenoxaprofen may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinBenoxaprofen may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GentamicinBenoxaprofen may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1ABenoxaprofen may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GinsengThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Ginseng.Approved, Investigational, Nutraceutical
GlipizideThe protein binding of Glipizide can be decreased when combined with Benoxaprofen.Approved, Investigational
GlyburideThe protein binding of Glyburide can be decreased when combined with Benoxaprofen.Approved
GrepafloxacinBenoxaprofen may increase the neuroexcitatory activities of Grepafloxacin.Approved, Investigational, Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Guacetisal.Experimental
GuanfacineThe therapeutic efficacy of Guanfacine can be decreased when used in combination with Benoxaprofen.Approved, Investigational
HalcinonideThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Halcinonide.Approved, Investigational, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when Benoxaprofen is combined with HE3286.Investigational
HeparinBenoxaprofen may increase the anticoagulant activities of Heparin.Approved, Investigational
HigenamineThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Higenamine.Investigational
HydralazineBenoxaprofen may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Benoxaprofen.Approved, Vet Approved
HydrocortisoneThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Benoxaprofen.Approved, Vet Approved
Hydrocortisone acetateThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone acetate is combined with Benoxaprofen.Approved, Vet Approved
Hydrocortisone butyrateThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone butyrate is combined with Benoxaprofen.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Benoxaprofen.Approved, Investigational
Hygromycin BBenoxaprofen may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe risk or severity of gastrointestinal bleeding can be increased when Benoxaprofen is combined with Ibandronate.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Benoxaprofen.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Ibuproxam.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Icatibant.Approved, Investigational
IcosapentThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Icosapent.Approved, Nutraceutical
IdraparinuxBenoxaprofen may increase the anticoagulant activities of Idraparinux.Investigational
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Benoxaprofen.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Imidapril.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Imidazole salicylate.Experimental
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Benoxaprofen.Approved
IndenololBenoxaprofen may decrease the antihypertensive activities of Indenolol.Withdrawn
IndobufenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Indobufen.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Indomethacin.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Indoprofen.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Benoxaprofen.Approved, Investigational
IsepamicinBenoxaprofen may decrease the excretion rate of Isepamicin which could result in a higher serum level.Experimental
IsoxicamThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Isoxicam.Withdrawn
IsradipineThe therapeutic efficacy of Isradipine can be decreased when used in combination with Benoxaprofen.Approved, Investigational
IstaroximeThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Istaroxime.Investigational
KanamycinBenoxaprofen may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Investigational, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Kebuzone.Experimental
KetoprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Ketoprofen.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Benoxaprofen.Approved
LabetalolBenoxaprofen may decrease the antihypertensive activities of Labetalol.Approved
LacidipineThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Benoxaprofen.Approved, Investigational
LandiololBenoxaprofen may decrease the antihypertensive activities of Landiolol.Investigational
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Benoxaprofen.Approved, Investigational
Latanoprostene BunodThe therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Benoxaprofen.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Benoxaprofen.Approved, Investigational
LepirudinBenoxaprofen may increase the anticoagulant activities of Lepirudin.Approved
LercanidipineThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Benoxaprofen.Approved, Investigational
LetaxabanBenoxaprofen may increase the anticoagulant activities of Letaxaban.Investigational
LevobetaxololBenoxaprofen may decrease the antihypertensive activities of Levobetaxolol.Approved, Investigational
LevobunololBenoxaprofen may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinBenoxaprofen may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Benoxaprofen.Approved, Investigational
LisinoprilThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Lisinopril.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Lisofylline.Investigational
Lithium cationThe serum concentration of Lithium can be increased when it is combined with Benoxaprofen.Experimental
LomefloxacinBenoxaprofen may increase the neuroexcitatory activities of Lomefloxacin.Approved, Investigational
LonazolacThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Lonazolac.Experimental
LornoxicamThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Lornoxicam.Approved, Investigational
LosartanThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Benoxaprofen.Approved
LoteprednolThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Loteprednol.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Loxoprofen.Approved, Investigational
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Benoxaprofen.Approved, Investigational
LumiracoxibThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Lumiracoxib.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Benoxaprofen.Vet Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Magnesium salicylate.Approved
ManidipineThe therapeutic efficacy of Manidipine can be decreased when used in combination with Benoxaprofen.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Benoxaprofen.Approved, Investigational
ME-609The risk or severity of adverse effects can be increased when Benoxaprofen is combined with ME-609.Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Meclofenamic acid.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Mefenamic acid.Approved
MelagatranBenoxaprofen may increase the anticoagulant activities of Melagatran.Experimental
MelengestrolThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Meloxicam.Approved, Vet Approved
MepindololBenoxaprofen may decrease the antihypertensive activities of Mepindolol.Experimental
MesalazineThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Mesalazine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Metamizole.Approved, Investigational, Withdrawn
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Benoxaprofen.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Benoxaprofen.Approved
MethylprednisoloneThe risk or severity of gastrointestinal irritation can be increased when Methylprednisolone is combined with Benoxaprofen.Approved, Vet Approved
MetipranololBenoxaprofen may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Benoxaprofen.Approved
MetoprololBenoxaprofen may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MibefradilThe therapeutic efficacy of Mibefradil can be decreased when used in combination with Benoxaprofen.Investigational, Withdrawn
MicronomicinBenoxaprofen may decrease the excretion rate of Micronomicin which could result in a higher serum level.Experimental
MifamurtideThe therapeutic efficacy of Mifamurtide can be decreased when used in combination with Benoxaprofen.Approved, Experimental
MinoxidilThe therapeutic efficacy of Minoxidil can be decreased when used in combination with Benoxaprofen.Approved, Investigational
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Benoxaprofen.Approved
MizoribineThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Mizoribine.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Moexipril.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Mofebutazone.Experimental
MometasoneThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Mometasone.Approved, Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Benoxaprofen.Approved
MoxifloxacinBenoxaprofen may increase the neuroexcitatory activities of Moxifloxacin.Approved, Investigational
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Benoxaprofen.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Benoxaprofen.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Nabumetone.Approved
NadololBenoxaprofen may decrease the antihypertensive activities of Nadolol.Approved
NadroparinBenoxaprofen may increase the anticoagulant activities of Nadroparin.Approved, Investigational
NafamostatBenoxaprofen may increase the anticoagulant activities of Nafamostat.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Benoxaprofen.Approved
NaftopidilThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Benoxaprofen.Investigational
Nalidixic AcidBenoxaprofen may increase the neuroexcitatory activities of Nalidixic Acid.Approved, Investigational
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Benoxaprofen.Approved, Vet Approved
NCX 1022The risk or severity of adverse effects can be increased when Benoxaprofen is combined with NCX 1022.Investigational
NeamineBenoxaprofen may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NebivololBenoxaprofen may decrease the antihypertensive activities of Nebivolol.Approved, Investigational
NemonoxacinBenoxaprofen may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinThe risk or severity of nephrotoxicity can be increased when Benoxaprofen is combined with Neomycin.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Nepafenac.Approved, Investigational
NetilmicinBenoxaprofen may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Investigational
NicardipineThe therapeutic efficacy of Nicardipine can be decreased when used in combination with Benoxaprofen.Approved, Investigational
NifenazoneThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Nifenazone.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Niflumic Acid.Approved
NiguldipineThe therapeutic efficacy of Niguldipine can be decreased when used in combination with Benoxaprofen.Experimental
NilvadipineThe therapeutic efficacy of Nilvadipine can be decreased when used in combination with Benoxaprofen.Approved, Investigational
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Benoxaprofen.Approved, Investigational, Withdrawn
NimodipineThe therapeutic efficacy of Nimodipine can be decreased when used in combination with Benoxaprofen.Approved, Investigational
NisoldipineThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Benoxaprofen.Approved
NitrendipineThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Benoxaprofen.Approved, Investigational
NitroaspirinThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Nitroaspirin.Investigational
NorfloxacinBenoxaprofen may increase the neuroexcitatory activities of Norfloxacin.Approved
OfloxacinBenoxaprofen may increase the neuroexcitatory activities of Ofloxacin.Approved
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Oleoyl-estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Benoxaprofen.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Benoxaprofen.Approved
OlsalazineBenoxaprofen may increase the nephrotoxic activities of Olsalazine.Approved
Omacetaxine mepesuccinateThe risk or severity of bleeding can be increased when Benoxaprofen is combined with Omacetaxine mepesuccinate.Approved, Investigational
OmapatrilatThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Omapatrilat.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Orgotein.Vet Approved
OtamixabanBenoxaprofen may increase the anticoagulant activities of Otamixaban.Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Oxaprozin.Approved
Oxolinic acidBenoxaprofen may increase the neuroexcitatory activities of Oxolinic acid.Experimental
OxprenololBenoxaprofen may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Benoxaprofen.Approved, Withdrawn
PalmidrolThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Palmidrol.Experimental, Nutraceutical
PamidronateThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Pamidronate.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Parecoxib.Approved
ParomomycinThe risk or severity of nephrotoxicity can be increased when Benoxaprofen is combined with Paromomycin.Approved, Investigational
ParthenolideThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Parthenolide.Approved, Investigational
PazufloxacinBenoxaprofen may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinBenoxaprofen may increase the neuroexcitatory activities of Pefloxacin.Approved
PenbutololBenoxaprofen may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
Pentaerythritol TetranitrateBenoxaprofen may increase the anticoagulant activities of Pentaerythritol Tetranitrate.Approved
Pentosan PolysulfateBenoxaprofen may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Perindopril.Approved
PhenindioneBenoxaprofen may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenprocoumonBenoxaprofen may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenylbutazoneThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Phenylbutazone.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Benoxaprofen.Approved, Investigational
PindololBenoxaprofen may decrease the antihypertensive activities of Pindolol.Approved, Investigational
Pipemidic acidBenoxaprofen may increase the neuroexcitatory activities of Pipemidic acid.Experimental
PiretanideThe therapeutic efficacy of Piretanide can be decreased when used in combination with Benoxaprofen.Approved
PirfenidoneThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Pirfenidone.Approved, Investigational
Piromidic acidBenoxaprofen may increase the neuroexcitatory activities of Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Piroxicam.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Pirprofen.Experimental
PitolisantThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Pitolisant.Approved, Investigational
Platelet Activating FactorBenoxaprofen may decrease the antihypertensive activities of Platelet Activating Factor.Experimental
PlazomicinBenoxaprofen may decrease the excretion rate of Plazomicin which could result in a higher serum level.Approved, Investigational
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Benoxaprofen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Pomalidomide.Approved
Potassium CitrateBenoxaprofen may increase the anticoagulant activities of Potassium Citrate.Approved, Investigational, Vet Approved
PractololBenoxaprofen may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Benoxaprofen.Approved, Investigational
PranoprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Pranoprofen.Experimental, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Prasterone.Approved, Investigational, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Prasterone sulfate.Investigational
PrednicarbateThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Prednicarbate.Approved, Investigational
PrednisoloneThe risk or severity of gastrointestinal irritation can be increased when Prednisolone is combined with Benoxaprofen.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Pregnenolone.Approved, Experimental, Investigational
ProbenecidThe serum concentration of Benoxaprofen can be increased when it is combined with Probenecid.Approved, Investigational
ProglumetacinThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Proglumetacin.Experimental
PropacetamolThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Propacetamol.Approved, Investigational
PropafenoneBenoxaprofen may decrease the antihypertensive activities of Propafenone.Approved
PropranololBenoxaprofen may decrease the antihypertensive activities of Propranolol.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Propyphenazone.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Proquazone.Experimental
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Benoxaprofen.Experimental
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Benoxaprofen.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Benoxaprofen.Vet Approved
Protein CBenoxaprofen may increase the anticoagulant activities of Protein C.Approved
Protein S humanBenoxaprofen may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeBenoxaprofen may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinBenoxaprofen may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when Benoxaprofen is combined with PTC299.Investigational
PuromycinBenoxaprofen may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
QuinaprilThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Quinapril.Approved, Investigational
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Benoxaprofen.Approved
RamiprilThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Ramipril.Approved
RescinnamineThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Rescinnamine.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Resveratrol.Approved, Experimental, Investigational
ReviparinBenoxaprofen may increase the anticoagulant activities of Reviparin.Approved, Investigational
RibostamycinBenoxaprofen may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Investigational
RimexoloneThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Rimexolone.Approved
RisedronateThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Risedronate.Approved, Investigational
RivaroxabanBenoxaprofen may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Rofecoxib.Approved, Investigational, Withdrawn
RosoxacinBenoxaprofen may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational
RufloxacinBenoxaprofen may increase the neuroexcitatory activities of Rufloxacin.Experimental
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Benoxaprofen.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Salicylamide.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Benoxaprofen.Approved, Investigational, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Salsalate.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Benoxaprofen.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Benoxaprofen.Investigational
SarilumabSarilumab may increase the immunosuppressive activities of Benoxaprofen.Approved, Investigational
SeliciclibThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Seliciclib.Investigational
SemapimodThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Semapimod.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Seratrodast.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Serrapeptase.Investigational
SisomicinBenoxaprofen may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SitafloxacinBenoxaprofen may increase the neuroexcitatory activities of Sitafloxacin.Experimental, Investigational
Sodium CitrateThe risk or severity of bleeding and hemorrhage can be increased when Benoxaprofen is combined with Sodium Citrate.Approved, Investigational
Sodium phosphate, monobasicThe risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Benoxaprofen.Approved
SotalolBenoxaprofen may decrease the antihypertensive activities of Sotalol.Approved
SparfloxacinBenoxaprofen may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
SpiraprilThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Spirapril.Approved
SpironolactoneThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Benoxaprofen is combined with Spironolactone.Approved
SRT501The risk or severity of adverse effects can be increased when Benoxaprofen is combined with SRT501.Investigational
StreptomycinBenoxaprofen may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Benoxaprofen.Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Benoxaprofen.Approved, Investigational
SulodexideBenoxaprofen may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Benoxaprofen.Investigational
SuprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Suprofen.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Suxibuzone.Experimental
TacrolimusBenoxaprofen may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Benoxaprofen.Approved
TalinololBenoxaprofen may decrease the antihypertensive activities of Talinolol.Investigational
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Benoxaprofen.Approved
TarenflurbilThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Tarenflurbil.Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Benoxaprofen.Approved
Technetium Tc-99m etidronateThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Technetium Tc-99m etidronate.Approved
Technetium Tc-99m medronateThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Technetium Tc-99m medronate.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Benoxaprofen.Approved, Investigational
TemafloxacinBenoxaprofen may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Temocapril.Experimental, Investigational
TenidapThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Tenidap.Experimental
Tenofovir disoproxilThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Tenofovir disoproxil.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Tenoxicam.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Tepoxalin.Vet Approved
TerbutalineBenoxaprofen may decrease the antihypertensive activities of Terbutaline.Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Teriflunomide.Approved
TertatololBenoxaprofen may decrease the antihypertensive activities of Tertatolol.Experimental
TetrahydropalmatineThe therapeutic efficacy of Tetrahydropalmatine can be decreased when used in combination with Benoxaprofen.Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Tiaprofenic acid.Approved
Tiludronic acidThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Tiludronic acid.Approved, Investigational, Vet Approved
TimololBenoxaprofen may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Tinoridine.Investigational
TixocortolThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Tixocortol.Approved, Withdrawn
TobramycinBenoxaprofen may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Tolfenamic Acid.Approved, Investigational
TolmetinThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Tolmetin.Approved
TorasemideThe therapeutic efficacy of Torasemide can be decreased when used in combination with Benoxaprofen.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Trandolapril.Approved
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Benoxaprofen.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Benoxaprofen.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Triamcinolone.Approved, Vet Approved
TriamtereneBenoxaprofen may decrease the antihypertensive activities of Triamterene.Approved
TribenosideThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Tribenoside.Experimental
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Benoxaprofen.Approved, Vet Approved
TriptolideThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Triptolide.Investigational
Trolamine salicylateThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Trolamine salicylate.Approved
TrovafloxacinBenoxaprofen may increase the neuroexcitatory activities of Trovafloxacin.Approved, Investigational, Withdrawn
TroxerutinBenoxaprofen may increase the anticoagulant activities of Troxerutin.Investigational
UlobetasolThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Ulobetasol.Approved
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Benoxaprofen.Approved, Investigational
ValdecoxibThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Valdecoxib.Approved, Investigational, Withdrawn
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Benoxaprofen.Approved, Investigational
VancomycinBenoxaprofen may decrease the excretion rate of Vancomycin which could result in a higher serum level.Approved
WarfarinBenoxaprofen may increase the anticoagulant activities of Warfarin.Approved
XimelagatranBenoxaprofen may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
ZaltoprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Zaltoprofen.Approved, Investigational
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Benoxaprofen.Approved, Investigational, Withdrawn
ZofenoprilThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Zofenopril.Experimental
Zoledronic acidThe risk or severity of gastrointestinal bleeding can be increased when Benoxaprofen is combined with Zoledronic acid.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Zomepirac.Withdrawn
Food Interactions
Not Available

References

Synthesis Reference

Evans, D., Dunwell, D.W. and Hicks, A.; US. Patent 3,912, 18; October 14, 1975; assigned to Lilly Industries Ltd. Evans, D., Dunwell, D.W. and Hicks, T.A.; U.S. Patent 3,962,441; June 8, 1976; assigned to Lilly Industries, Ltd. Evans, D., Dunwell, D.W. and Hicks, T.A.; US. Patent 3,962,452; June 8, 1976; assigned to Lilly Industries, Ltd.

General References
Not Available
External Links
PubChem Compound
39941
PubChem Substance
46508496
ChemSpider
36518
ChEBI
76114
ChEMBL
CHEMBL340978
Therapeutic Targets Database
DCL000338
PharmGKB
PA166049178
Wikipedia
Benoxaprofen
ATC Codes
M01AE06 — Benoxaprofen

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)196Evans, D., Dunwell, D.W. and Hicks, A.; US. Patent 3,912, 18; October 14, 1975; assigned to Lilly Industries Ltd. Evans, D., Dunwell, D.W. and Hicks, T.A.; U.S. Patent 3,962,441; June 8, 1976; assigned to Lilly Industries, Ltd. Evans, D., Dunwell, D.W. and Hicks, T.A.; US. Patent 3,962,452; June 8, 1976; assigned to Lilly Industries, Ltd.
logP3.23JACK,DB ET AL. (1988)
Predicted Properties
PropertyValueSource
Water Solubility0.0317 mg/mLALOGPS
logP4.22ALOGPS
logP4.13ChemAxon
logS-4ALOGPS
pKa (Strongest Acidic)4.66ChemAxon
pKa (Strongest Basic)0.091ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area63.33 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity88.51 m3·mol-1ChemAxon
Polarizability31.34 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9799
Caco-2 permeable-0.5319
P-glycoprotein substrateNon-substrate0.8015
P-glycoprotein inhibitor INon-inhibitor0.9594
P-glycoprotein inhibitor IINon-inhibitor0.8703
Renal organic cation transporterNon-inhibitor0.92
CYP450 2C9 substrateNon-substrate0.7222
CYP450 2D6 substrateNon-substrate0.7458
CYP450 3A4 substrateNon-substrate0.5062
CYP450 1A2 substrateInhibitor0.6452
CYP450 2C9 inhibitorNon-inhibitor0.8178
CYP450 2D6 inhibitorNon-inhibitor0.9669
CYP450 2C19 inhibitorNon-inhibitor0.6701
CYP450 3A4 inhibitorNon-inhibitor0.9678
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7368
Ames testNon AMES toxic0.9206
CarcinogenicityNon-carcinogens0.8368
BiodegradationNot ready biodegradable0.9684
Rat acute toxicity3.3303 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9951
hERG inhibition (predictor II)Non-inhibitor0.9003
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Download (8.83 KB)
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
GC-MS Spectrum - EI-BGC-MSsplash10-0a4i-7294000000-6fce0cace9618294c879
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenyl-1,3-oxazoles. These are aromatic heterocyclic compounds containing a 1,3-oxazole substituted at one or more positions by a phenyl group.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Azoles
Sub Class
Oxazoles
Direct Parent
Phenyl-1,3-oxazoles
Alternative Parents
Benzoxazoles / Chlorobenzenes / Aryl chlorides / Heteroaromatic compounds / Oxacyclic compounds / Monocarboxylic acids and derivatives / Carboxylic acids / Azacyclic compounds / Organopnictogen compounds / Organonitrogen compounds
show 4 more
Substituents
Phenyl-1,3-oxazole / Benzoxazole / Chlorobenzene / Halobenzene / Aryl chloride / Aryl halide / Monocyclic benzene moiety / Benzenoid / Heteroaromatic compound / Carboxylic acid derivative
show 15 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
1,3-benzoxazoles, monocarboxylic acid, monochlorobenzenes (CHEBI:76114)

Drug created on September 11, 2007 14:01 / Updated on August 02, 2018 05:26